Bausch & Lomb Corp (New York Stock Exchange:BLCO)
| Market Cap | $6.93B+25.4% |
| Revenue (ttm) | $5.41B+8.8% |
| Net Income | -$111.00M+63.6% |
| EPS | -$0.31+64.2% |
| Shares Out | 357.50M |
| PE Ratio | n/a |
| Forward PE | 16.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 871,551 |
| Open | $20.43 |
| Previous Close | $20.69 |
| Day's Range | $19.30 - $20.43 |
| 52-Week Range | $14.65 - $21.40 |
| Beta | 0.52 |
| Analysts | Hold |
| Price Target | $21.75(+12.23%) |
| Earnings Date | Feb 17, 2027 |
About BLCO
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating BLCO in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 17, 2027Earnings report
$BLCO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BLCO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BLCO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BLCO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BLCO Revenue by Segment or Geography
| Vision Care | $774.00M | 32.48% |
| Devices | $517.00M | 21.70% |
| OTC | $477.00M | 20.02% |
| Pharmaceuticals | $319.00M | 13.39% |
| Surgical | $234.00M | 9.82% |
| Branded and Other Generics | $58.00M | 2.43% |
| Other revenues | $4.00M | 0.17% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BLCO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BLCO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BLCO
| MGMTBallast Small/Mid Cap ETF | $2.68M |
| ARWGArcher Growth ETF | $363.32K |
| DFAXDimensional World ex U.S. Core Equity 2 ETF | $314.12K |
| PDNInvesco RAFI Developed Markets ex-U.S. Small-Mid ETF | $189.76K |
| GVLUGotham 1000 Value ETF | $118.39K |
| DFICDimensional - International Core Equity 2 ETF | $75.68K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BLCO’s recent data — informational, not investment advice
What’s Behind the Score
News check: BL1332 Phase 2 trial missed primary endpoint for post-surgical ocular pain, a significant clinical setback weighing on stock performance.
Recent Insider Activity
Insider Score Trend Over Time
-35.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
